ADAR1 Capital Management, LLC

ADAR1 Capital Management, LLC is a declared insider at 6 companies; the most frequent names are InMed Pharmaceuticals Inc., NextCure, Inc. and Tenax Therapeutics, Inc. In total, 51 filings cover trades dated from 9 August 2024 to 21 October 2026.

On the open market, the record shows 47 purchases worth €8.9M and 1 sale worth €66.9M. Taken together, the sales exceed the purchases by €58.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 3 share grants. Since January 2026: 45 purchases and no sales on the market.

Half of the purchases are above €48k and half below. Measured against the company's value, the median purchase equals 0.28% of market capitalisation, across 42 purchases where it is known. Of 43 purchases, 1 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 10 purchases show a median change of +5.3%, with the price up in 50% of them. They describe history only and say nothing certain about the share price ahead.

Most recently, on 21 October 2026, the filings show an open-market purchase worth €451k in Tenax Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.